Alexion Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$172.0M
Doctors Paid
60,943
Transactions
266,980
2024 Total
$33.9M
Payment Breakdown by Category
Research$107.8M (62.7%)
Consulting$12.0M (7.0%)
Food & Beverage$6.9M (4.0%)
Travel$6.1M (3.6%)
Royalty/License$2.2M (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $107.8M | 11,700 | 62.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28.4M | 11,586 | 16.5% |
| Consulting Fee | $12.0M | 3,949 | 7.0% |
| Food and Beverage | $6.9M | 205,186 | 4.0% |
| Travel and Lodging | $6.1M | 19,117 | 3.6% |
| Honoraria | $4.8M | 2,655 | 2.8% |
| Space rental or facility fees (teaching hospital only) | $2.3M | 619 | 1.3% |
| Royalty or License | $2.2M | 50 | 1.3% |
| Grant | $901,442 | 29 | 0.5% |
| Education | $576,318 | 12,024 | 0.3% |
| Charitable Contribution | $25,266 | 65 | 0.0% |
Payments by Type
Research
$107.8M
11,700 transactions
General
$64.2M
255,280 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) | $11.8M | 3 | 170 |
| A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. | $10.6M | 0 | 140 |
| A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. | $4.3M | 0 | 113 |
| A Phase 1, Open label, Dose escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults with Hypophosphatasia | $3.4M | 0 | 5 |
| A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome | $3.2M | 0 | 337 |
| A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA, ANDEXANET ALFA FOR INJECTION, IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR | $2.4M | 0 | 100 |
| An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis | $2.2M | 0 | 650 |
| Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement Inhibitor Naive Adult Patients With Generalized Myasthenia Gravis | $2.2M | 0 | 96 |
| A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) | $2.2M | 1 | 41 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis | $2.1M | 2 | 372 |
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS) | $2.0M | 5 | 584 |
| Eneboparatide - Calypso study which is a pivotal phase 3 study investigational therapeutic peptide with a novel mechanism of action for hypoparathyroidism | $2.0M | 0 | 17 |
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | $1.9M | 52 | 450 |
| A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients PREVENT Study | $1.9M | 0 | 512 |
| An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients | $1.7M | 0 | 900 |
| A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthe | $1.6M | 0 | 83 |
| A Phase 3, Randomized, Rater Blinded, Multi Center Study to Evaluate the Efficacy and Safety of ALXN1840 (WTX101) Administered for 48 Weeks versus Standard of Care in Patients with Wilson Disease Aged 12 Years and Older, with an Extension Period of up to 60 Months | $1.4M | 0 | 23 |
| A Phase 3, Open label, Single Arm, Multicenter Study of Ravulizumab in Pediatric Patients with Persistent Complement Mediated Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT) | $1.4M | 0 | 58 |
| An Observational, Longitudinal, Prospective, Long term Registry of Patients with Hypophosphatasia | $1.4M | 0 | 91 |
| Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months | $1.3M | 7 | 59 |
| A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | $1.2M | 0 | 54 |
| A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL) | $1.0M | 1 | 56 |
| A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) | $946,813 | 4 | 99 |
| A Phase 2, Open Label, Multicenter Dose Selection Study to Evaluate the Safety and Tolerability of CAEL 101 in Patients with AL Amyloidosis | $933,044 | 0 | 10 |
| Safety, Pharmacokinetics, and PharmacodynamicsEfficacy of SBC-103 in MPS IIIB | $910,564 | 0 | 41 |
| Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Nave Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome aHUS | $855,663 | 4 | 308 |
| ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria PNH Currently Treated With Eculizumab | $851,271 | 0 | 344 |
| Atypcial Hemolytic-Uremic Syndrome aHUS Registry | $808,784 | 14 | 330 |
| A Phase 2 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis | $774,410 | 0 | 38 |
| ALXN2050 HV 109 Hepatic Impairment (mild & moderate) Ph 1 study | $749,489 | 0 | 8 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Ilene Weitz, M.d, M.D | Hematology | Los Angeles, CA | $739,260 | $0 |
| Darius Moshfeghi, Md, MD | Ophthalmology | Palo Alto, CA | $721,034 | $0 |
| Jeffrey Laurence, Md, MD | Hematology & Oncology | New York, NY | $615,284 | $0 |
| Dr. Suraj Muley, Md, MD | Neurology | Phoenix, AZ | $557,437 | $0 |
| Dr. Eric Rush, M.d, M.D | Clinical Genetics (M.D.) | Kansas City, MO | $556,183 | $0 |
| Dr. Jamie Koprivnikar, M.d, M.D | Hematology | Hackensack, NJ | $530,671 | $0 |
| Dr. Tuan Vu, Md, MD | Neurology | Tampa, FL | $523,011 | $0 |
| Anthony Chang, Md, MD | Anatomic Pathology & Clinical Pathology | Burr Ridge, IL | $513,246 | $0 |
| Dr. Bhupendra Khatri, M.d, M.D | Neurology | Milwaukee, WI | $437,833 | $0 |
| Dr. Leonard Bell, M.d, M.D | Specialist | Woodbridge, CT | $424,131 | $0 |
| Damian Laber, Md, MD | Hematology & Oncology | Tampa, FL | $419,068 | $0 |
| Dr. Andrew Gordon, M.d, M.D | Neurology | Lake Barrington, IL | $377,072 | $0 |
| Dr. Savneek Chugh, M.d, M.D | Nephrology | Hawthorne, NY | $340,144 | $0 |
| Bart Scott | Medical Oncology | Seattle, WA | $331,354 | $0 |
| Dr. Richard Burwick, M.d., M.p.h, M.D., M.P.H | Obstetrics & Gynecology | West Covina, CA | $329,764 | $0 |
| Dr. Gregory Greenwood, M.d, M.D | Internal Medicine | Winston-Salem, NC | $326,351 | $0 |
| Jamile Shammo, M.d, M.D | Hematology | Chicago, IL | $308,085 | $0 |
| Dr. Virginia Araiza, M.d, M.D | Pediatric Endocrinology | Houston, TX | $305,477 | $0 |
| Dr. Ahmed Obeidat, M.d., P.h.d, M.D., P.H.D | Neurology with Special Qualifications in Child Neurology | Milwaukee, WI | $305,349 | $0 |
| Edward George, Md, MD | Specialist | Norfolk, VA | $298,932 | $0 |
| Unknown Provider | — | — | $286,384 | $0 |
| Dr. Raghav Govindarajan, Md, MD | Neurology | O Fallon, IL | $277,529 | $0 |
| Benjamin Osborne | Neurology | Washington, DC | $269,461 | $0 |
| Perry Shieh, Md, MD | Neuromuscular Medicine | Los Angeles, CA | $259,760 | $0 |
| Dr. Ramy Hanna, M.d, M.D | Nephrology | Orange, CA | $258,964 | $0 |
Ad
Top Products
- SOLIRIS $28.8M
- ULTOMIRIS $22.6M
Associated Products (9)
Payment Categories
- Food & Beverage $6.9M
- Consulting $12.0M
- Travel & Lodging $6.1M
- Research $107.8M
- Royalties $2.2M
About Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. has made $172.0M in payments to 60,943 healthcare providers, recorded across 266,980 transactions in the CMS Open Payments database. In 2024, the company paid $33.9M. The top product by payment volume is SOLIRIS ($28.8M).
Payments were distributed across 306 medical specialties. The top specialty by payment amount is Neurology ($15.5M to 5,378 doctors).
Payment categories include: Food & Beverage ($6.9M), Consulting ($12.0M), Research ($107.8M), Travel & Lodging ($6.1M), Royalties ($2.2M).
Alexion Pharmaceuticals, Inc. is associated with 9 products in the CMS Open Payments database, including SOLIRIS, ULTOMIRIS, and Strensiq.